Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 2/20 | 0.41 |
| ▸ | LSS | P48449 | 1/20 | 0.36 |
| ▸ | ASAH1 | Q13510 | 5/20 | 0.35 |
| ▸ | HTR6 | P50406 | 3/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6782259 | 0.73 | QDPR (0.48) | QDPRDRD2SLC6A4HTR1DLSS | |
| SCHEMBL6845639 | 0.72 | HTR1D (0.43) | HTR1DHTR6 | |
| SCHEMBL7253016 | 0.72 | HTR1D (0.76) | QDPRHTR1DLSSHTR6 | |
| SCHEMBL6845729 | 0.69 | QDPR (0.47) | QDPRHTR1D | |
| SCHEMBL14571688 | 0.69 | QDPR (0.53) | QDPRDRD2SLC6A4LSSASAH1 | |
| SCHEMBL17683262 | 0.68 | HTR1D (0.49) | QDPRDRD2SLC6A4HTR1D | |
| SCHEMBL10268348 | 0.67 | SLC6A4 (0.69) | QDPRDRD2SLC6A4LSSHTR6 | |
| SCHEMBL10004175 | 0.66 | HTR6 (0.53) | DRD2HTR6DRD3HRH3 | |
| SCHEMBL27878763 | 0.66 | HTR1D (0.57) | DRD2SLC6A4HTR1DDRD3 | |
| SCHEMBL15317630 | 0.64 | QDPR (0.50) | QDPRDRD2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | SCN7A, CNR2, HTR7 | QDPR 495/4885DRD2 437/4885SLC6A4 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.